SAN DIEGO — Pfizer’s abrupt withdrawal of its sickle cell drug Oxybryta over safety concerns was called “tone deaf” during a ...

A federal judge has ordered the U.S. Food and Drug Administration to publicly disclose more information underpinning its ...

Severe hemophilia A is a genetic disorder that prevents blood from clotting properly, posing a constant risk of dangerous ...

Stem cell transplantation is used to treat several types of blood cancers, but carries the risk of a life-threatening side effect called graft-versus-host disease. Results from a clinical trial showed ...

Man becomes first in Indiana to undergo gene therapy for hemophilia B. The procedure aims to address the root cause of the ...

The healthcare industry thrives due to novel drug pipeline discoveries, AI integration to streamline processes and ...

As chronic and infectious diseases continue to rise, the demand for advanced healthcare solutions grows. Hence, investing in ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine ...

DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding ...

FDA approves ... Shows Competitive Edge Against Pfizer’s Tafamidisa In Lucrative But Competitive ATTR-CM Market Attruby is the first and only approved product with a label specifying near ...

On Friday, the FDA approved BridgeBio ... Competitive Edge Against Pfizer’s Tafamidisa In Lucrative But Competitive ATTR-CM Market Attruby is the first and only approved product with a label ...

Twiist was approved by the FDA ... and Pfizer’s Trazimera. Both treat patients HER2-overexpressing metastatic breast cancer, and both are preferred over Herceptin and other biosimilars, including ...